全身TNF-α抑制剂使用与原发性开角型青光眼风险的相关性
这项回顾性多中心队列研究比较了使用与未使用全身TNF-α抑制剂的患者,发现用药者10年内原发性开角型青光眼诊断风险较低(2.0% vs 3.3%;HR 0.70)。阿达木单抗和英夫利西单抗使用者风险也较低,提示TNF-α介导的炎症可能参与青光眼性神经退变。
要点
- 全身TNF-α抑制剂使用与10年原发性开角型青光眼风险降低相关(HR 0.70)。
- 阿达木单抗和英夫利西单抗使用者风险分别降低(HR 0.74和0.68)。
- 不同TNF-α抑制剂之间两两比较未见显著差异。
核心结论
- 全身TNF-α抑制剂使用,特别是阿达木单抗和英夫利西单抗,与长期原发性开角型青光眼风险适度但显著降低相关。
研究设计与样本
- 回顾性多中心临床队列研究,使用美国70家医疗机构去标识化电子健康记录(2006-2026年)。
- 纳入≥40岁患者,TNF-α抑制剂使用者按人口学和全身适应症1:1倾向性匹配无暴露对照。
- 排除有葡萄膜炎及相关后遗症病史者,分析11,915对匹配配对。
主要发现
- 10年时TNF-α抑制剂使用者原发性开角型青光眼诊断风险低于对照(2.0% vs 3.3%;HR 0.70 [95% CI 0.59-0.82];P<.001)。
- 阿达木单抗使用者(每组n=4,962)风险较低(HR 0.74 [95% CI 0.57-0.96])。
- 英夫利西单抗使用者(每组n=2,134)风险较低(HR 0.68 [95% CI 0.47-0.97])。
- TNF-α抑制剂之间两两比较未见显著差异。
关键数值与推荐
- 原发性开角型青光眼新诊断通过ICD-10编码在10年随访内识别。
- 匹配队列平均(SD)年龄59(10)岁,女性占68%。
- TNF-α抑制剂包括阿达木单抗、英夫利西单抗、依那西普、 certolizumab pegol或戈利木单抗。
临床怎么用
- 使用全身TNF-α抑制剂的患者可能具有较低的原发性开角型青光眼长期风险,尤其是阿达木单抗和英夫利西单抗使用者。
- 这一关联支持TNF-α介导的炎症在青光眼性神经退变中的潜在作用,但需进一步研究确认因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the association between systemic tumor necrosis factor-alpha (TNF-α) inhibitor use and the long-term risk of primary open angle glaucoma (POAG), and to compare glaucoma risk among users of different TNF-α inhibitors. DESIGN: Retrospective, multicenter clinical cohort study. METHODS: This retrospective, multicenter cohort study compared patients ≥40 years with and without TNF-α inhibitor use (2006-2026) using data from aggregated, de-identified electronic health records across 70 U.S. health care organizations. Patients prescribed TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, or golimumab) were propensity matched (1:1) to controls without TNF-α inhibitor exposure based on demographics and systemic indications for TNF-a. Patients with a history of uveitis and related sequelae were excluded. New POAG diagnosis, identified by ICD-10 codes within 10 years of follow-up, was assessed using Cox proportional hazards models. RESULTS: Among 12,227 TNF-α inhibitor users and 1,354,651 controls, 11,915 matched pairs were analyzed (mean [SD] age 59 [10] years; 68% female). At 10 years, TNF-α inhibitor users were associated with a lower risk of POAG diagnosis compared to controls (2.0% vs. 3.3%; HR 0.70 [95% CI 0.59-0.82]; P<.001) In agent-specific analysis, adalimumab-users (n=4,962 per cohort) (HR 0.74 [0.57-0.96]) and infliximab users (n=2,134 per cohort; HR 0.68 [95% CI 0.47-0.97) were associated with a lower risk of POAG diagnosis compared to matched controls. No significant differences were observed in pairwise comparisons amongst TNF-α inhibitors. CONCLUSIONS: Systemic TNF-α inhibitor use, particularly adalimumab and infliximab, was associated with a modest but significant reduction in long-term POAG risk. These findings support a potential role of TNF-α-mediated inflammation in glaucomatous neurodegeneration.
引用
- Hong AT, Lin F, Xu BY, et al. Association Between Systemic TNF-α Inhibitor Use and Risk of Primary Open-Angle Glaucoma. Am J Ophthalmol. 2026. PMID: 42913929. doi:10.1016/j.ajo.2026.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。